Interojo Inc. (KOSDAQ:119610)
13,930
+10 (0.07%)
Sep 18, 2026, 3:30 PM KST
Interojo Revenue
Interojo had revenue of 29.45B KRW in the quarter ending June 30, 2026, a decrease of -6.02%. This brings the company's revenue in the last twelve months to 124.14B, up 12.83% year-over-year. In the year 2025, Interojo had annual revenue of 118.44B with 2.24% growth.
Revenue (ttm)
124.14B
Revenue Growth
+12.83%
P/S Ratio
1.26
Revenue / Employee
165.97M
Employees
748
Market Cap
156.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.44B | 2.60B | 2.24% |
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| ALTEOGEN | 254.01B |
| Daihan Pharmaceutical | 216.55B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |
| Hana Pharm | 139.33B |